We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Structural Studies Reveal Molecular Basis for Bacterial Motility in the Urinary Tract

By LabMedica International staff writers
Posted on 23 Mar 2016
A team of molecular microbiologists has unraveled the mechanism used by Escherichia coli bacteria to bind to cells lining the urinary tract and explained how the pathogen migrates to the bladder despite the strong force of urine flowing in the other direction. More...


E. coli attaches to host epithelia via the fimbrial adhesion FimH, a two-domain protein at the tip of type I pili recognizing terminal mannoses on epithelial glycoproteins.

Investigators at the University of Basel (Switzerland) and ETH Zurich (Switzerland) established a model system for fimbrial FimH function. A fimbril is a proteinaceous appendage in many gram-negative bacteria that is thinner and shorter than a flagellum.

The investigators revealed, in a paper published in the March 7, 2016, online edition of the journal Nature Communications, a three-state mechanism of FimH catch-bond formation based on crystal structures of all states, kinetic analysis of ligand interaction, and molecular dynamics simulations. They found that FimH bound to sugar structures on the cell surface increasingly tightly the more it was pulled. As strong tensile forces developed during urination, FimH protected the bacteria from being flushed out. In the absence of tensile force, the FimH pilin domain allosterically accelerated spontaneous ligand dissociation from the FimH lectin domain by 100,000-fold, resulting in weak affinity and allowing the bacteria to release from the cell surface and migrate in the direction of the bladder.

“Through the combination of several biophysical and biochemical methods, we have been able to elucidate the binding behavior of FimH in more detail than ever before”, said senior author Dr. Rudolf Glockshuber, professor of molecular biology and biophysics at ETH Zurich. “The protein FimH is composed of two parts, of which the second non-sugar binding part regulates how tightly the first part binds to the sugar molecule. When the force of the urine stream pulls apart the two protein domains, the sugar binding site snaps shut. However, when the tensile force subsides, the binding pocket reopens. Now the bacteria can detach and swim upstream the urethra.”

Related Links:
University of Basel
ETH Zurich



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.